Side effects of systemic oncological therapies in dermatology

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Lisa ZimmerDirk Schadendorf

Abstract

The discovery of specific gene mutations, termed "driver mutations", in different tumors has brought personalized medicine into the focus of cancer treatment. Targeted treatment agents generally are administered orally and have a tolerable adverse event profile; they have become widely used in both inpatient and outpatient settings. The approval of the selective BRAF inhibitor vemurafenib (Zelboraf®) as first-line therapy of metastatic melanoma in Europe in February 2012 as well as the increasing use of MEK inhibitors within clinical trials confronts dermatologists and oncologists with a new spectrum of side effects. Knowledge of these possible adverse events and their management will be crucial for optimized patient care. This article offers an overview of the most important adverse events of currently employed dermato-oncologic therapeutic agents.

References

Oct 1, 1993·Cancer Treatment Reviews·R PazdurM N Raber
May 1, 1996·Southern Medical Journal·J Y PayneK Dhingra
Sep 1, 1996·Medical and Pediatric Oncology·M J McCartyS J Vukelja
Jan 1, 1995·Investigational New Drugs·C J LinkE Reed
Sep 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerL Kanz
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ Belinson
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R MiddletonN Thatcher
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars MeyerHanno Riess
Apr 21, 2004·Journal of the American Academy of Dermatology·Regina TreudlerConstantin E Orfanos
Feb 19, 2005·Seminars in Oncology·Susan E KrownJ Simon Stewart
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Jul 5, 2005·The Lancet Oncology·Caroline RobertThierry Le Chevalier
Mar 2, 2006·Annales de dermatologie et de vénéréologie·A LevyN Basset-Seguin
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LorussoG Scambia
Mar 12, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roger von MoosAxel Hauschild
Mar 18, 2008·Journal of the American Academy of Dermatology·Noushin HeidarySusan Burgin
Apr 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A AdjeiS Gail Eckhardt
May 16, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Katharina C KählerAxel Hauschild
Nov 11, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Jens UlrichSelma Ugurel
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karin SchadReinhard Dummer
May 21, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette DegenRalf Gutzmer
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Oct 28, 2010·Investigational New Drugs·Yevgeniy BalagulaPatricia L Myskowski
Nov 19, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Katharina C Kähler, Axel Hauschild
Dec 31, 2010·Current Opinion in Oncology·Caroline RobertChristine Mateus
May 25, 2011·Nature Reviews. Clinical Oncology·Antoni Ribas, Keith T Flaherty
Jun 2, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mario E LacoutureUNKNOWN MASCC Skin Toxicity Study Group
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jul 28, 2011·OncoTargets and Therapy·Yutaka YamamotoHirotaka Iwase
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan BaschUNKNOWN American Society of Clinical Oncology
Oct 15, 2011·The New England Journal of Medicine·Hiroyuki Morita, Ryozo Nagai
Oct 15, 2011·The New England Journal of Medicine·Jason P Lott
Oct 28, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Zahra HanaiziFrancesco Pignatti
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OberholzerLevi A Garraway
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
Feb 3, 2012·The New England Journal of Medicine·Reinhard DummerSimone M Goldinger
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Mar 2, 2012·Journal of Oncology Practice·Ethan BaschGary H Lyman
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa ZimmerDirk Schadendorf

❮ Previous
Next ❯

Citations

Mar 22, 2013·PloS One·Jeannine D RinderknechtBenedetta Belloni
May 14, 2014·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K Maleki, E Weisshaar
May 14, 2014·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·L M EhmannB Homey
Dec 30, 2015·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Thomas WiederMartin Röcken
Jul 25, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette DegenRalf Gutzmer
Dec 10, 2013·The Australasian Journal of Dermatology·Rachael AnforthPablo Fernandez-Peñas
Jul 19, 2014·American Journal of Ophthalmology·Christina H ChoeRavi K Amaravadi
Jan 17, 2015·Journal of the American Academy of Dermatology·James B MacdonaldAleksandar Sekulic
May 15, 2018·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Giovanni DamianiUNKNOWN OncoSkin working group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.